4.2 Article

Genetic predictors of response to antidepressants in the GENDEP project

期刊

PHARMACOGENOMICS JOURNAL
卷 9, 期 4, 页码 225-233

出版社

SPRINGERNATURE
DOI: 10.1038/tpj.2009.12

关键词

depression; antidepressants; pharmacogenetics; serotonin; norepinephrine; glucocorticoid receptor

资金

  1. European Commission [LSHB-CT-2003-503428]
  2. Biomedical Research Centre for Mental Health at the Institute of Psychiatry
  3. King's College London
  4. South London and Maudsley NHS Foundation Trust
  5. National Institute for Health Research, Department of Health, UK
  6. GlaxoSmithKline

向作者/读者索取更多资源

The objective of the Genome-based Therapeutic Drugs for Depression study is to investigate the function of variations in genes encoding key proteins in serotonin, norepinephrine, neurotrophic and glucocorticoid signaling in determining the response to serotonin-reuptake-inhibiting and norepinephrine-reuptake-inhibiting antidepressants. A total of 116 single nucleotide polymorphisms in 10 candidate genes were genotyped in 760 adult patients with moderate-to-severe depression, treated with escitalopram (a serotonin reuptake inhibitor) or nortriptyline (a norepinephrine reuptake inhibitor) for 12 weeks in an open-label part-randomized multicenter study. The effect of genetic variants on change in depressive symptoms was evaluated using mixed linear models. Several variants in a serotonin receptor gene (HTR2A) predicted response to escitalopram with one marker (rs9316233) explaining 1.1% of variance (P = 0.0016). Variants in the norepinephrine transporter gene (SLC6A2) predicted response to nortriptyline, and variants in the glucocorticoid receptor gene (NR3C1) predicted response to both antidepressants. Two HTR2A markers remained significant after hypothesis-wide correction for multiple testing. A false discovery rate of 0.106 for the three strongest associations indicated that the multiple findings are unlikely to be false positives. The pattern of associations indicated a degree of specificity with variants in genes encoding proteins in serotonin signaling influencing response to the serotonin-reuptake-inhibiting escitalopram, genes encoding proteins in norepinephrine signaling influencing response to the norepinephrine-reuptake-inhibiting nortriptyline and a common pathway gene influencing response to both antidepressants. The single marker associations explained only a small proportion of variance in response to antidepressants, indicating a need for a multivariate approach to prediction. The Pharmacogenomics Journal (2009) 9, 225-233; doi: 10.1038/tpj.2009.12; published online 14 April 2009

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据